Chiesi Group Company Profile
The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.
Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.
Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.
Location
Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Parma
43100
Italy
Contact
Phone: 39 0521 2791
Fax: 39 0521 774468
Email: info@chiesigroup.com
News Articles
[Chiesi], [Eddingpharm] form JV, [Chiesi Edding Hong Kong]
[Chiesi Farmaceutici SPA] and [Eddingpharm International Holdings Ltd.] have formed [Chiesi Edding Hong Kong Ltd.], a joint venture which will focus on marketing respiratory therapeutics in China. The...
Chiesi Prepared To Pay Cash For Remaining 40% Of Cornerstone
Italian pharmaceutical company Chiesi is looking to buy up the remainder of Cornerstone Therapeutics, a company that already markets Chiesi’s products in the U.S. and is financially linked with the...
Chiesi Farmaceutici establishes new Mexico affiliate, views growth
Privately-owned Italian drugmaker Chiesi Farmaceutici says it has recently opened its 25th affiliate, Chiesi Mexico, representing a milestone in the company's internationalisation plan, which began in...
Eddingpharm and Chiesi Farmaceutici Form Asthma Drug JV
Eddingpharm has formed a JV with Chiesi Farmaceutici that will market two of Chiesi’s asthma drugs in China. Eddingpharm distributes western drugs in China. The JV is owned 51% by Eddingpharm an...
Cornerstone receives proposal to go private
Cornerstone Therapeutics Inc. (NASDAQ:CRTX) said its board received a proposal from partner Chiesi Farmaceutici S.p.A. (Parma, Italy) to take Cornerstone private. Chiesi, which owns about 60% of Corne...
Special Cornerstone committee will consider Chiesi buyout as profit-loss ratio stagnates
Cornerstone Therapeutics formed a special committee with five independent directors to develop a response to the Cary, North Carolina-based company's largest shareholder – the Chiesi Group of Pa...
Kamada cosies up with Chiesi for inhaled alpha-1 product
Kamada of Israel has signed an exclusive distribution agreement with Chiesi Farmaceutici of Italy for Kamada's experimental inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficie...
Cornerstone taps Chiesi link as it hones hospital focus with anti-infective
Cornerstone Therapeutics' stock price ticked slightly higher on 8 November, but closed down 0.6% on news that the Cary, North Carolina-based company licensed exclusive US rights to Chiesi Farmaceutic...
Drugs and Medications
Curosurf [Cornerstone Therapeutics Inc.]
CUROSURF (poractant alfa)Intratracheal Suspension
Ethyl alcohol [H and P Industries, Inc. dba Triad Group]
DRUG FACTS
DRUG FACTS
Alba hawaiian coconut siscreen spf 15 [The Hain Celestial Group, Inc.]
Drug Facts
Glycerin [H and P Industries, Inc. dba Triad Group]
DRUG FACTS
PubMed Articles
Plume temperature emitted from metered dose inhalers.
The temperature of the drug cloud emitted from a pressurised metered dose inhaler (pMDI) may result in patient discomfort and inconsistent or non-existent dose delivery to the lungs. The effects of va...
The novel quaternary ammonium salt, CHF5407, showed subnanomolar affinities for human muscarinic M1, M2 and M3 receptors, and dissociated very slowly (t1/2 = 166 min from hM3 receptors (t1/2 = 166 min...
Clinical Trials
The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...
The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...
Short Term Group Therapy for OCD
Assessing OCD before and after group therapy
Psychological Prevention of Internalizing Disorders
The purpose of this study is to determine whether cognitive-behavioral group prevention (CBT-G) for german children is effective and to what extent parental group training moderates outcom...
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the pati...
Companies
The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research...
Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3...
W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital...
PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...
Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...
More Information about "Chiesi Group" on BioPortfolio
We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.
